Rak pluća - literatura, knjige i časopisi

http://www.hzjz.hr/rak
Literatura: Marušić A., Anatomija čovjeka, Medicinska naklada 2002

Šamija M, Vrdoljak E, Krajina Z. (ur.) Klinička onkologija, Medicinska naklada Zagreb, 2006

Potporno liječenje

29. Lyman GH, Morrison VA, Dale DC et al. OPPS Working Group ANC Study Group. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.Leuk Lymphoma 2003;44:2069-76.
30. Wolff DA, Crawford J,Dale DC, Poniewierski MS,Lyman GH. Risk of neutropenic complications based on prospective nationwide registry of cancer patients initiating systematic chemotherapy. Proc Am Soc Clin Oncol 2004;23:547. (abstract 6125)
31. Lyman GH, Delgado DJ. Risk and timing of hospitalisation for febrile neutropenia in patients receiving CHOP, CHOP-R or CNOP chemotherapy for intermediate grade non-Hodgkin's lymphoma. Cancer 2003;98:2402-9.
32. Meza L,Baselga J, Holmes FA, Liang B, Breddy J for the Pegfilgrastim Study Group. Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 2002;21:255b. (abstract 2840). 
33. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-37.
34. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-37.
35. Aapro MS, Cameron DA,Pettengell R, Bohlius J et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006;42:2433-53
36. Hughes W, Armstrong D, Bodey G et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751
37. Morisson VA, Picozzi V, Scott S, Pohlman B et al. The impact of age on delivered dose intensity and hospitalisation for febrile neutropenia in patients with intermediate-grade non Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factors analysis. Clinical Lymphoma 2001,Vol 2, No.1,47-56
38. Kuderer NM, Dale DC,Crawford J, et al. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;Vol 106,No.10:2258-2266
39. Šamija,Vrdoljak,Krajina i sur.Klinička onkologija,Medicinska naklada, 2006.
40. NCCN Practice Guidelines in Oncology-Antiemesis,v.1.2010.
41. Gralow J, Tripathy D. Managing metastatic bone pain: The role of bisphosphonates. J Pain Symptom Manage 2007; 33: 462-472    
42.  Conte PF, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol 2004; 31: 59-63